Distribution of controlled substances in the U.S. supply chain: where does the compass point?

Abstract

Recent administrative actions taken by the Drug Enforcement Administration (DEA) in Florida have prompted an articulate and detailed discussion of the pharmaceutical supply chain for controlled substances. Current practices in commercial distribution systems may have a partial nexus to the proliferation of opioid prescription drug abuse in Florida. No single factor or entity is responsible for this abuse proliferation, and there is no intent to harm consumers; however, distribution practices are adding risk to public health. This commentary extends a discussion on supply chain practices that seem misaligned in the promotion of legitimate business objectives and advancing public health.